•
KY
KYTX
Kyverna Therapeutics, Inc. Common Stock
yahooBIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
--
Price Chart
Market Cap
565.07M
Volume
117.74K
52W High
$13.67
52W Low
$1.78
Open
$0.00
Prev Close
$9.48
Day Range
0.00 - 0.00
About Kyverna Therapeutics, Inc. Common Stock
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Latest News
How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next?
Benzinga•Dec 31
Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock
Benzinga•Dec 17
Stock Market Today, Dec. 15: U.S Stocks Ease as Investors Wait for Rate Clarity
The Motley Fool•Dec 15
Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome
GlobeNewswire Inc.•Dec 14
Diffuse Cutaneous Systemic Sclerosis Market Forecast: Opportunities and Growth Trends Upto 2034 | DelveInsight
GlobeNewswire Inc.•Oct 6
Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event
GlobeNewswire Inc.•Aug 28
Notice to Long-Term Shareholders of Archer-Daniels-Midland Co. (NYSE: ADM); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Kyverna Therapeutics, Inc. (Nasdaq: KYTX); and Mercury Systems, Inc. (Nasdaq: MRCY): Grabar Law Office is Investigating Claims on Your Behalf
GlobeNewswire Inc.•Mar 18
Long-Term Shareholder Notice: Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims on Your Behalf
GlobeNewswire Inc.•Mar 13